12 October 2016 - Viamet Pharmaceuticals today announced that the U.S. FDA has granted Qualified Infectious Disease Product and fast track designations to VT-1161, a novel oral agent for the treatment of recurrent vulvovaginal candidiasis, a common and difficult to treat condition in women.

There are no approved therapies in the United States for recurrent vulvovaginal candidiasis.

VT-1161, the company’s lead product candidate, is nearing completion of Phase 2b testing for the oral treatment of RVVC and onychomycosis, a highly prevalent fungal infection of the nail. Viamet is also developing VT-1129, currently in Phase 1 testing for the treatment of cryptococcal meningitis, a life-threatening fungal infection of the brain, and VT-1598 for the treatment of coccidioidomycosis, or Valley Fever.

Read Viamet Pharmaceuticals press release